The announcement comes just a few months after WHO released its 2024 Bacterial Priority Pathogens List, which highlights the ...

Novo Nordisk has shared promising results from a late-stage study of semaglutide in patients with metabolic ...

The National Institute for Health and Care Excellence (NICE) has recommended Blueprint Medicines’ Ayvakyt (avapritinib) to ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the European Commission (EC) to treat eosinophilic ...

The companies will use Ascendis’ TransCon technology to develop therapies for metabolic and cardiovascular diseases ...

Around 86% of clinical trials do not meet patient recruitment goals, ultimately failing to improve patient outcomes and ...

EatMoreFruit, a UK top 10 independent healthcare communication agency, today announced the launch of its European Network to ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved CStone Pharmaceuticals’ sugemalimab as part of a first-line combination treatment for lung cancer. The anti-PD-L1 monoclonal ...

Johnson & Johnson (J&J) has announced that its pan-FGFR tyrosine kinase inhibitor Balversa (erdafitinib) has been granted marketing authorisation by the Medicines and Healthcare products Regulatory ...

GSK has announced that it will be expanding its immunology pipeline by acquiring a clinical-stage T cell-engager from Chimagen Biosciences in a deal worth $850m. GSK said it plans to develop and ...

The US Food and Drug Administration (FDA) has approved Journey Medical’s Emrosi (minocycline hydrochloride extended release capsules 40mg) to treat inflammatory lesions of rosacea in adults. Affecting ...